Thr33
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr33  -  TTK (human)

Site Information
kFkNEDLtDELsLNK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2846502

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 , 18 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 2 , 3 , 6 , 7 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 37 , 38 ) , mass spectrometry (in vitro) ( 34 ) , mutation of modification site ( 2 , 8 , 18 , 34 ) , phospho-antibody ( 1 , 2 , 4 ) , western blotting ( 2 , 4 )
Disease tissue studied:
bone cancer ( 2 ) , breast cancer ( 7 , 12 ) , breast ductal carcinoma ( 7 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 ) , cervical cancer ( 2 , 32 ) , cervical adenocarcinoma ( 2 , 32 ) , colorectal cancer ( 4 , 18 , 34 ) , colorectal carcinoma ( 4 , 18 , 34 ) , lung cancer ( 12 ) , non-small cell lung cancer ( 12 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
TTK (human) ( 2 , 8 )
Kinases, in vitro:
PLK1 (human) ( 5 ) , TTK (human) ( 34 , 38 )
Putative upstream phosphatases:
PPP2R5D (human) ( 1 )
Treatments:
AZ3146 ( 4 ) , BI2536 ( 25 ) , CCT251455 ( 4 ) , MG132_withdrawal ( 27 ) , MLN8054 ( 25 ) , nocodazole ( 35 ) , siRNA ( 1 ) , thymidine ( 35 )

Downstream Regulation
Effects of modification on TTK:
enzymatic activity, induced ( 5 ) , enzymatic activity, inhibited ( 2 ) , intracellular localization ( 5 , 8 )
Effects of modification on biological processes:
cell cycle regulation ( 8 )

References 

1

Hayward D, et al. (2019) Checkpoint signaling and error correction require regulation of the MPS1 T-loop by PP2A-B56. J Cell Biol 218, 3188-3199
31511308   Curated Info

2

Combes G, et al. (2018) Mps1 Phosphorylates Its N-Terminal Extension to Relieve Autoinhibition and Activate the Spindle Assembly Checkpoint. Curr Biol 28, 872-883.e5
29502948   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Gurden MD, et al. (2015) Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Res 75, 3340-54
26202014   Curated Info

5

von Schubert C, et al. (2015) Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human Cells. Cell Rep 12, 66-78
26119734   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Wang X, et al. (2014) Dynamic autophosphorylation of mps1 kinase is required for faithful mitotic progression. PLoS One 9, e104723
25265012   Curated Info

9

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

10

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

11

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

12

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

13

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

14

Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -;
Curated Info

15

Rikova K (2011) CST Curation Set: 13127; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

16

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

17

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

18

Zhang X, et al. (2011) Two LXXLL motifs in the N terminus of Mps1 are required for Mps1 nuclear import during G(2)/M transition and sustained spindle checkpoint responses. Cell Cycle 10, 2742-50
21778823   Curated Info

19

Guo A (2011) CST Curation Set: 12077; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

20

Guo A (2011) CST Curation Set: 12078; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

21

Guo A (2011) CST Curation Set: 11846; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

22

Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

23

Guo A (2011) CST Curation Set: 11850; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

24

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

25

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

26

Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12
22067460   Curated Info

27

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

28

Guo A (2010) CST Curation Set: 6268; Year: 2010; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

29

Guo A (2010) CST Curation Set: 6269; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

30

Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

31

Possemato A (2010) CST Curation Set: 9444; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

32

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

33

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

34

Xu Q, et al. (2009) Regulation of kinetochore recruitment of two essential mitotic spindle checkpoint proteins by Mps1 phosphorylation. Mol Biol Cell 20, 10-20
18923149   Curated Info

35

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

36

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

37

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

38

Jelluma N, et al. (2008) Chromosomal instability by inefficient Mps1 auto-activation due to a weakened mitotic checkpoint and lagging chromosomes. PLoS One 3, e2415
18545697   Curated Info